Analytical Overview of a Life-Saving Drug: Paxlovid in the Treatment of COVID-19

The paper was Analytical Overview of a Life-Saving Drug: Paxlovid in the Treatment of COVID-19. The outbreak of COVID-19 triggered a global health emergency and a rapid pursuit of effective therapeutics. Paxlovid, a combination of Nirmatrelvir and Ritonavir, emerged as one of the most promising oral antiviral treatments for COVID-19, especially in high-risk patients. This comprehensive analytical overview explores the drug's development, pharmacological properties, clinical efficacy, pharmacokinetics, side effects, resistance concerns, public health significance, and implications for future pandemics. As COVID-19 continues to evolve, understanding the role and performance of Paxlovid remains crucial in global health management. This paper aims to provide a comprehensive, analytical review of Paxlovid, detailing its pharmacological structure, clinical outcomes, accessibility, and future prospects of the a qualitative, descriptive-analytical design aimed at synthesizing clinical, pharmacological, regulatory, and public health data on Paxlovid.